Cancer Drug

The Chinese developer of next-generation cancer treatments is raking in huge returns from its flagship drug, but R&D and sales costs keep rising.

BeiGene still bleeding red ink despite blockbuster drug

The Chinese developer of next-generation cancer treatments is raking in huge returns from its flagship drug, but R&D and sales costs keep rising Key Takeaways: The Chinese biotech reported a…
BGNE.US 6160.HK 688235.SHG

FAST NEWS: Nomura takes up Kintor Pharma stake

The latest: Japanese financial group Nomura Holdings disclosed it purchased 5.91 million shares of Kintor Pharmaceutical Ltd. (9939.HK) on Jun. 1, raising its stake in the biotech company from 4.06% to 5.39%,…
9939.HK

Recent Articles

RELATED ARTICLES

  1. BeiGene was slapped with a patent lawsuit by U.S. rival AbbVie in June, and suffered another blow to its global ambitions in July when Novartis pulled out of a drug collaboration.
    Sales success comes with side effects for drug maker BeiGene
    BGNE.US 6160.HK
  2. BeiGene goes for global growth with sales and R&D push
    BGNE.US 6160.HK
  3. Heated market for dueling blood cancer drugs lands BeiGene in court
    BGNE.US 6160.HK
  4. FAST NEWS: Beigene stock falls after Novartis terminates partnership
    BGNE.US 6160.HK
  5. Drug maker Junshi seeks Swiss cure for cash woes
    1877.HK 688150.SHG
  6. AstraZeneca pays hefty price for Chinese weight-loss drug
    AZN.US
  7. Akeso marks profit milestone with swift rights issue
    9926.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo File-alt

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners